Methods
Multicenter, cross-sectional study of all HIV-infected patients on regular follow-up in five Andalusian hospitals (southern Spain) during March-August 2007. A questionnaire about cardiovascular risk factors (CVR) and a physical exam, including anthropometric parameters and blood pressure, were done in all cases. Recent fasting lab data (≤3 prior months) were available in all cases, which included lipid profile, glycaemia, CD4 cells count, and HIV viral load. Statistical analysis: SPSS 11.0.
Summary of results
Data are from 1,072 patients, 43.8% of whom had low HDL-C. The prevalence of low HDL-C was higher among patients diagnosed with AIDS than those without AIDS (47.7 vs. 41.1%; p = 0.037), those not on ART than those who were on ART (53.4 vs. 42.5; p = 0.01), those with detectable HIV viral load (55.2 vs. 40.2; p < 0.0001), with CD4 cell counts ≤350 cells/μL (53.9 vs. 40.1%; p < 0.0001), smokers than no smokers (46.8 vs. 38.8%; p = 0.014), and those with hypertriglyceridemia (58.6 vs. 34.3%; p < 0.0001). For patients on ART, the prevalence of low HDL-C was higher for those on PI than those taking NNRTI (52.1 vs. 31.4%; p < 0.0001). In the multivariate analysis, the following factors remained significant: tobacco use (OR 1.37, 95% CI 1,04-1.8; p = 0.04), hypertriglyceridemia (OR 2.94, 95% CI 2.2-3.8; p < 0.00001), CD4 cells count ≤350 cells/μL (OR 1.74, 95% CI 1.2-2.3; p < 0.0001), and detectable HIV viral load (OR 1.85, 95% CI 1.3-2.5; p < 0.0001).
Conclusion
Immunological and virological situation, in addition to traditional cardiovascular risk factors such as tobacco and hypertriglyceridemia, affect HDL-C levels in HIV-infected patients. For patients on ART, the use of PI is associated with a higher probability of low levels of HDL-C. Although it is not clear if the higher HDL-C levels associated with ART use are surrogates for decreased CVD risk, this may be another reason to start ART earlier.
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